Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.68
NAS:ALKS's Cash-to-Debt is ranked lower than
75% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ALKS: 1.68 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.53 Max: No Debt
Current: 1.68
Equity-to-Asset 0.70
NAS:ALKS's Equity-to-Asset is ranked higher than
53% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALKS: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.66 Max: 0.97
Current: 0.7
-0.15
0.97
Piotroski F-Score: 4
Altman Z-Score: 10.16
Beneish M-Score: -2.73
WACC vs ROIC
15.13%
-19.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -25.96
NAS:ALKS's Operating Margin % is ranked higher than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ALKS: -25.96 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -18.36 Max: 41.29
Current: -25.96
-35.7
41.29
Net Margin % -25.61
NAS:ALKS's Net Margin % is ranked higher than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:ALKS: -25.61 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -13.55 Max: 69.37
Current: -25.61
-36.15
69.37
ROE % -16.27
NAS:ALKS's ROE % is ranked higher than
65% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ALKS: -16.27 )
Ranked among companies with meaningful ROE % only.
NAS:ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -5.96 Max: 65.64
Current: -16.27
-18.25
65.64
ROA % -11.43
NAS:ALKS's ROA % is ranked higher than
66% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:ALKS: -11.43 )
Ranked among companies with meaningful ROA % only.
NAS:ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -4.55 Max: 27.26
Current: -11.43
-12.04
27.26
ROC (Joel Greenblatt) % -57.83
NAS:ALKS's ROC (Joel Greenblatt) % is ranked higher than
66% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:ALKS: -57.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.03  Med: -16.97 Max: 131.93
Current: -57.83
-61.03
131.93
3-Year Revenue Growth Rate 5.50
NAS:ALKS's 3-Year Revenue Growth Rate is ranked higher than
54% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ALKS: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 9.9 Max: 69.6
Current: 5.5
-20.2
69.6
GuruFocus has detected 2 Warning Signs with Alkermes PLC $NAS:ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALKS's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SGEN, NAS:JAZZ, NAS:TSRO, NAS:ALNY, NAS:EXEL, NAS:IONS, NAS:BIVV, NAS:UTHR, NAS:KITE, OTCPK:NVZMY, NAS:ARIA, OTCPK:UCBJY, NAS:BLUE, NAS:TECH, NAS:CLVS, NAS:NBIX, NAS:GLPG, OTCPK:GMXAY, OTCPK:PPTDF, NAS:ACAD » details
Traded in other countries:8AK.Germany,
Headquarter Location:Ireland
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Top Ranked Articles about Alkermes PLC

Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 1111.11
NAS:ALKS's Forward PE Ratio is ranked lower than
100% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. NAS:ALKS: 1111.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 7.33
NAS:ALKS's PB Ratio is ranked lower than
75% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:ALKS: 7.33 )
Ranked among companies with meaningful PB Ratio only.
NAS:ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.26 Max: 11.68
Current: 7.33
1.66
11.68
PS Ratio 11.35
NAS:ALKS's PS Ratio is ranked higher than
52% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NAS:ALKS: 11.35 )
Ranked among companies with meaningful PS Ratio only.
NAS:ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.19  Med: 7.11 Max: 18.85
Current: 11.35
2.19
18.85
Current Ratio 3.60
NAS:ALKS's Current Ratio is ranked lower than
54% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:ALKS: 3.60 )
Ranked among companies with meaningful Current Ratio only.
NAS:ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.22 Max: 35.69
Current: 3.6
2.01
35.69
Quick Ratio 3.30
NAS:ALKS's Quick Ratio is ranked lower than
54% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ALKS: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
NAS:ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.99 Max: 35.69
Current: 3.3
1.95
35.69
Days Inventory 138.89
NAS:ALKS's Days Inventory is ranked lower than
52% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. NAS:ALKS: 138.89 )
Ranked among companies with meaningful Days Inventory only.
NAS:ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 128.98 Max: 166.33
Current: 138.89
86.09
166.33
Days Sales Outstanding 82.51
NAS:ALKS's Days Sales Outstanding is ranked lower than
62% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:ALKS: 82.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.54
Current: 82.51
27.46
93.54
Days Payable 142.92
NAS:ALKS's Days Payable is ranked higher than
77% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NAS:ALKS: 142.92 )
Ranked among companies with meaningful Days Payable only.
NAS:ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 142.92
Current: 142.92
39.15
142.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
NAS:ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:ALKS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -10.2 Max: 2.1
Current: -4.5
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 36.44
NAS:ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:ALKS: 36.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.18  Med: 7.26 Max: 343
Current: 36.44
2.18
343
Price-to-Tangible-Book 10.88
NAS:ALKS's Price-to-Tangible-Book is ranked lower than
78% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:ALKS: 10.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 7.69 Max: 365.22
Current: 10.88
1.24
365.22
Price-to-Intrinsic-Value-Projected-FCF 10.84
NAS:ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. NAS:ALKS: 10.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NAS:ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2  Med: 4.05 Max: 20.95
Current: 10.84
2
20.95
Price-to-Median-PS-Value 1.60
NAS:ALKS's Price-to-Median-PS-Value is ranked lower than
78% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAS:ALKS: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAS:ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.56 Max: 14.45
Current: 1.6
0.38
14.45
Earnings Yield (Greenblatt) % -2.23
NAS:ALKS's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:ALKS: -2.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6  Med: -0.5 Max: 53.4
Current: -2.23
-6
53.4

More Statistics

Revenue (TTM) (Mil) $780.70
EPS (TTM) $ -1.31
Beta2.42
Short Percentage of Float10.11%
52-Week Range $39.65 - 63.40
Shares Outstanding (Mil)153.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 910 1,098 1,373
EPS ($) 0.05 0.65 1.71
EPS without NRI ($) 0.05 0.65 1.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}